Literature DB >> 826316

Activity of anthracyclines against an adriamycin (NSC-123127)-resistant subline of P388 leukemia with special emphasis on cinerubin A (NSC-18334).

R K Johnson, A A Ovejera, A Goldin.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 826316

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


× No keyword cloud information.
  8 in total

Review 1.  Anthracyclines--modern tumour-inhibiting agents.

Authors:  D G Strauss
Journal:  Folia Microbiol (Praha)       Date:  1978       Impact factor: 2.099

Review 2.  Tumour cell resistance to anthracyclines--a review.

Authors:  S Kaye; S Merry
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

3.  The mechanism and overcoming of resistance in ACNU-resistant sublines of C6 and 9L rat glioma.

Authors:  T Yoshida; K Shimizu; Y Ushio; T Hayakawa; H Mogami; Y Sakamoto
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

4.  Structural modification study of anthracyclinones: synthesis and biological activity of several derivatives of eta-pyrromycinone.

Authors:  D F Liu; H Xiong; C C Cheng
Journal:  Pharm Res       Date:  1992-06       Impact factor: 4.200

5.  Cross resistance to esters of methotrexate in a doxorubicin-resistant subline of P388 murine leukemia.

Authors:  A Ramu; M Fridkin; R Steinherz
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

6.  Patterns of cross-resistance in a multidrug-resistant small-cell lung carcinoma cell line.

Authors:  S P Cole
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

7.  Derivation and preliminary characterisation of adriamycin resistant lines of human lung cancer cells.

Authors:  P R Twentyman; N E Fox; K A Wright; N M Bleehen
Journal:  Br J Cancer       Date:  1986-04       Impact factor: 7.640

8.  5'-Nucleotidase activity and arachidonate metabolism in doxorubicin sensitive and resistant P388 cells.

Authors:  A Ramu; D Glaubiger; P Soprey; G H Reaman; N Feuerstein
Journal:  Br J Cancer       Date:  1984-04       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.